Plain-English translation of NCT06808477 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 clinical trial of , a new medication being tested to treat atopic dermatitis (a chronic skin condition causing severe itching and inflammation). The trial is studying how safe the medication is, how the body handles it, and whether it actually helps people with moderate to severe atopic dermatitis. The research includes testing in healthy volunteers first, and then in patients who have the condition.
Current treatments for severe atopic dermatitis don't work well enough for everyone, and some people cannot tolerate topical creams and ointments. This trial exists to see if the medication could offer a new option for patients who need better relief from this painful and exhausting skin condition.
You likely qualify if…
You likely don't qualify if…
Depending on which part of the study you join, you will receive either one injection or multiple injections (3–4 doses) of the medication or placebo over several weeks. Healthy volunteers come first to ensure safety, and then patients with atopic dermatitis receive the treatment. You will have regular visits to the clinic for blood tests, skin assessments, and check-ups to monitor how the medication affects you and whether your symptoms improve.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Australia
New Zealand